Stock Ratings / Health Care / TKNO / financials

NNNN (45) MYGN (39) ACHV (44) QDEL (30) ⌘ Pro Terminal →

Alpha Teknova Inc. (TKNO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.09 +2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Alpha Teknova Inc. (TKNO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $499.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TKNO)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TKNO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $36.7M

FY24

Rev $37.7M

FY25

Rev $40.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$40.5M	33.2%	-41.9%	-$17.3M	-$9.8M	-21.3%
FY 2024	$37.7M	19.2%	-69.3%	-$26.7M	-$13.5M	-26.3%
FY 2023	$36.7M	33.2%	-80%	-$36.8M	-$18.8M	-21.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TKNO)

✓Walkthrough of TKNO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TKNO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +127.89%▲ ASCENDING CHANNEL

2026-10-30O $8.01H $8.09L $7.11C $8.09VOL 651.1K

RES: $10.62SUP: $5.04SMA50: $7.71SMA200: $4.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TKNO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TKNO Butterfly Map → + Track TKNO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TKNO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TKNO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TKNO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TKNO)

Health Care Rank #507 of 1016 ⚔️ NNNN vs TKNO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TKNO vs. NNNN, MYGN, ACHV, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alpha Teknova Inc. (TKNO) ranks #507 by composite RQD confidence (44/100, grade D) and #453 by equity capitalization ($499.2M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with TKNO at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TKNO ACTIVE Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	Benchmark Subject
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-tkno →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-tkno →
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-tkno →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-tkno →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850902

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alpha Teknova Inc. (TKNO) reported GAAP revenue of $40.5M (+7.4% vs. FY2024 revenue of $37.7M , and +10.5% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$8.6M, and free cash flow of -$9.8M (+27.5% YoY). On the balance sheet, TKNO closed FY2025 with $103.6M in total assets against $0 in total debt (Altman Z-Score: 6.93, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.5M	-$17.3M	-$8.6M	-$9.8M	$103.6M	—
FY2024 (FY)	2024-12-31	$37.7M	-$26.7M	-$12.4M	-$13.5M	$118.8M	—
FY2023 (FY)	2023-12-31	$36.7M	-$36.8M	-$18.8M	-$18.8M	—	—

3. TKNO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TKNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alpha Teknova Inc. (NASDAQ: TKNO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $8.09 (+2.93% 1D, market cap $499.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TKNO ranks #507 in composite RQD confidence.

How does TKNO compare to NNNN and MYGN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TKNO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 33.2%, and ROIC of -21.3%. By comparison, NNNN (Anbio Biotechnology (Class A)) holds a D grade (45/100 RQD, P/E 83.6x, ROIC 17.0%, cap $535.3M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TKNO?

Per TKNO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850902), Alpha Teknova Inc. generated $40.5M in revenue (+7.4% YoY), -$17.3M in net income, and -$9.8M in free cash flow against $103.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TKNO trading relative to its 50-day, 200-day, and 52-week technical levels?

TKNO last traded at $8.09 (+2.93% on volume of 679,716 shares), positioning the stock +4.93% above its 50-day simple moving average ($7.71) and +65.78% above its 200-day simple moving average ($4.88). Across its 52-week range of $1.91 to $9.48, TKNO sits at the 81.6% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.08 to $9.10).